Transgene Stock Quote TNG - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.788

Bid

0.781

Ask

0.788

Volume

14,944

0.78 Day's Range 0.80

0.76 52 Week Range 1.52

Market Cap

79.472M

Previous Close

0.782

Open

0.79

Last Trade

0.788

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

34,859

Shares Outstanding

100,852,742

Dividend Yield

PE Ratio

-3.57

Earnings Per Share (EPS)

-0.22

Revenue

7.9M

Net Profit

-22.33M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.transgene.fr

Headquarters

Illkirch-graffenstaden, Bas-rhin, Fra

Founded

Transgene SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker TNG. The last closing price for Transgene was 0.78 €. Over the last year, Transgene shares have traded in a share price range of 0.76 € to 1.52 €.

Transgene currently has 100,852,742 shares outstanding. The market capitalization of Transgene is 78.87 € million. Transgene has a price to earnings ratio (PE ratio) of -3.57.

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data...

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Top line data show that the randomized...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.05	-5.96658711217	0.838	0.838	0.76	29161	0.78748416	DE
4	-0.138	-14.9028077754	0.926	0.964	0.76	40513	0.86634154	DE
12	-0.34	-30.1418439716	1.128	1.204	0.76	34859	0.98604941	DE
26	-0.536	-40.4833836858	1.324	1.35	0.76	30040	1.05785457	DE
52	-0.662	-45.6551724138	1.45	1.52	0.76	29773	1.17604595	DE
156	-1.622	-67.3029045643	2.41	2.99	0.76	38046	1.92820697	DE
260	-1.022	-56.4640883978	1.81	3.15	0.76	74399	1.98395186	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MLAAHAmatheon Agri Holding NV	0.02 € (100.00%)	5k
GNROGeNeuro SA	0.0768 € (25.49%)	200
BIDSGascogne DS	0.005 € (25.00%)	150.51k
ALSAFSAFE	0.11 € (23.73%)	39.98k
ALKKOKKO International SA	0.112 € (21.21%)	4.13M
ALIMOGroupimo	0.189 € (-40.94%)	392
MLUMGUmalis Group	1.30 € (-31.22%)	1.71k
MLNMAMiguet Et Associes	0.075 € (-24.62%)	1.72k
MLSEQSequa Petroleum NV	0.008 € (-20.00%)	23k
VACBSPierre & Vacances	0.05 € (-15.25%)	35.99k
BCPBanco Comercial Portugues SA	0.4446 € (-0.49%)	69.24M
ALNEVNeovacs	0.0002 € (0.00%)	41.4M
ALCYBCybergun	0.0001 € (0.00%)	30.32M
INGAING Groep NV	14.652 € (-1.16%)	14.06M
ACACredit Agricole SA	13.05 € (-1.66%)	8.06M